Hepatitis B vaccine
Hepatitis B universal vaccination: learning from the French experience
Sunday 19 December 2004
by
This update has been written for the numerous prescribers and health professionals who are logically disturbed by a growing discrepancy between the recommendation they are receiving of protecting public heath by hepatitis B vaccination and an accumulation of alarming data on the hazards of this prophylaxis.
Focused on a recent case/controls investigation which showed a 3-fold increase in the relative risk of multiple sclerosis after hepatitis B vaccine, this review was made upon systematic referencing from published or public data.
Marc Girard
Articles by this author
- P.C. Gøtzsche - La panique générale autour du coronavirus n’est pas justifiée (traduction)
- Les perles du coronavirus, du confinement, et (toujours) de la presse
- La CGT appelle à manifester contre la maladie de Lyme…
- Auditer les experts
- Élargissement des obligations vaccinales: mystérieuse épidémie chez les lanceurs d’alerte
- [...]
Keywords
-
Benefit/risk
- Vaccination contre l’hépatite B : essai de bilan chiffré
- Vaccin contre l’hépatite B : l’urgence d’une ré-évaluation
- Failure in drug safety assessment: a worrying issue far beyond manufacturer’s potential conflicts of interest
- Evaluation des statines
- Hepatitis B universal vaccination: learning from the French experience
- Evidence-based medicine (EBM)
- Hepatitis B
- Vaccine
Home |
Contact |
Site Map
| Log in |
Site statistics |
Visitors :
4655 /
1534232
en Documents in English Vaccines ?